Cardiovascular Clinical Studies

This channel includes news and new technology innovations from cardiovascular clinical trials. These clinical studies include all cardiac subspecialties.

Results of the PERFORMANCE II Trial were presented by William Gray, MD, System Chief, Division of Cardiovascular Diseases, Main Line Health, and Co-National Principal Investigator during the VIVA23 annual conference..

News | VIVA

PERFORMANCE II Carotid Stent Trial One-Year Outcomes Released at VIVA23

November 2, 2023 — Contego Medical Inc. announced the presentation of late-breaking clinical results from the ...

November 02, 2023

News | VIVA

VIVA23 Presents Outcomes of Late-breaking Science from Abbott’s LIFE-BTK, RESOLV FIH Study, and IN.PACT AV Access Trial

November 2, 2023 — The second round of late-breaking clinical trials results from the Vascular InterVentional Advances ...

November 01, 2023

News | VIVA

Vascular InterVentional Advances Conference, VIVA23, Clinical Trial Outcomes: PROMISE II (LimFlow) Trial for TADV, PRELUDE Study (LimbSonic) Therapeutic Ultrasound Presented

November 1, 2023 — The VIVA Foundation has announced the results for the first Late-Breaking Clinical Trial sessions at ...

November 01, 2023

Edwards Lifesciences Corporation (NYSE: EW) announced one-year results from CLASP IID, the first randomized controlled trial that directly compares two contemporary mitral transcatheter edge-to-edge repair (TEER) therapies

News | Structural Heart

CLASP IID One-year Data Confirm Safety and Efficacy of Edwards Pascal System for Degenerative Mitral Regurgitation

October 31, 2023 — Edwards Lifesciences Corporation announced one-year results from CLASP IID, the first randomized ...

October 31, 2023

The findings will impact the interventional treatment of High Bleeding Risk patients

News | Stents Drug Eluting

Positive Results Revealed in Clinical Trial COMPARE 60/80 for High Bleeding Risk Patients

October 31, 2023 — SMT (Sahajanand Medical Technologies), a leading medical device company in India, focused on ...

October 31, 2023

News | Ventricular Assist Devices (VAD)

Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy

October 31, 2023 — Tenaya Therapeutics, Inc., a clinical-stage biotechnology company with a mission to discover, develop ...

October 31, 2023

Data from first coronary DCB study in U.S. meet 12-month primary endpoint, demonstrate low adverse event rates with AGENT DCB

News | Drug-Eluting Balloons

Boston Scientific AGENT Drug-Coated Balloon Demonstrates Superiority to Uncoated Balloon Angioplasty in the AGENT IDE Trial

October 30, 2023 — Boston Scientific Corporation on Friday announced positive 12-month results from the pivotal AGENT ...

October 30, 2023

Abbott's landmark LIFE-BTK randomized clinical trial met its primary safety and effectiveness endpoints, demonstrating that Esprit BTK offers significant advancements in opening and keeping blocked arteries below-the-knee open compared to the standard of care, balloon angioplasty

News | Stents Bioresorbable

Late-breaking Data Show Esprit BTK Drug-eluting Resorbable Scaffold Reduces Chronic Limb-threatening Ischemia Progression Compared to the Standard of Care

October 30, 2023 — Abbott announced late-breaking data from the LIFE-BTK clinical trial evaluating the Esprit BTK ...

October 30, 2023

Key findings demonstrate patients with aortic stenosis have substantial untreated mortality risk across all levels of aortic stenosis severity, but aortic valve replacement rates remain low even for patients with severe aortic stenosis

News | Endovascular Aortic Repair

Philippe Généreux, MD Presents Novel Research on Aortic Stenosis from egnite, Inc.’s Database at TCT23

October 30, 2023 — -egnite, Inc., a leading cardiovascular digital health company, announced today that novel research ...

October 30, 2023

WATCH TAVR trial presented at the Transcatheter Cardiovascular Therapeutics annual conference

News | Cath Lab

iFR and FFR are Equally Safe to Diagnose and Treat Heart Disease According to Largest-ever Analysis of New Real-world, Long-term Data

October 26, 2023 — Royal Philips, a global leader in health technology, announced the latest results demonstrating the ...

October 26, 2023

New data presented at Transcatheter Cardiovascular Therapeutics (TCT) 2023 from the TRILUMINATE pivotal trial confirm safety, effectiveness and improvements in quality of life when treating tricuspid regurgitation (a leaky valve) with TriClip, an investigational device in the US

News | Structural Heart

Late-Breaking Data Showcase the Benefits of Abbott's Minimally Invasive Devices for People With Leaky Heart Valves

October 26, 2023 — Abbott announced data from late-breaking presentations showing the impact of its minimally invasive ...

October 26, 2023

New clinical data support use of lesion-specific FFRCT for diagnosis and treatment of patients with coronary artery disease

News | Computed Tomography (CT)

TCT 2023: HeartFlow Presents Clinical Data Featuring First Solution Offering Lesion-Specific Insights

October 26, 2023 — HeartFlow, Inc., a leader in non-invasive integrated artificial intelligence (AI) heart care ...

October 26, 2023

News | TCT

Six-Month Clinical Data from DESyne BDS Plus Randomized Controlled Trial (RCT) Presented at TCT 2023 Shines Spotlight on Safety, Effectiveness of World’s First Site-Specific Antithrombotic Drug Therapy

October 25, 2023 — Elixir Medical, developer of novel cardiovascular technologies, announced positive six-month clinical ...

October 25, 2023

TCT 2023: Medtronic adds to the body of evidence for Evolut TAVR with late-breaking clinical trial data from the Evolut Low Risk Trial

News | TCT

Medtronic Evolut TAVR Platform Outperforms Surgery with Sustained Valve Performance for Low-risk Patients at Four Years

October 25, 2023 — Medtronic plc, a global leader in healthcare technology, announced four-year results from the Evolut ...

October 25, 2023

Edwards Lifesciences announced new data from the PARTNER 3 trial demonstrating continued low rates of all-cause mortality, disabling stroke and rehospitalization at five years

News | Cardiovascular Surgery

Five-year Data from Partner 3 Trial Demonstrate Excellent Survival for Patients Receiving Edwards Sapien 3 Valve

October 25, 2023 — Edwards Lifesciences announced new data from the PARTNER 3 trial demonstrating continued low rates of ...

October 25, 2023